Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brümmendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus-Porta D.

Cancer Discov. 2012 Dec;2(12):1118-33. doi: 10.1158/2159-8290.CD-12-0210. Epub 2012 Sep 20.

2.

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Graus Porta D.

J Med Chem. 2011 Oct 27;54(20):7066-83. doi: 10.1021/jm2006222. Epub 2011 Sep 21.

PMID:
21936542
3.

Identification of Critical Molecular Components in a Multiscale Cancer Model Based on the Integration of Monte Carlo, Resampling, and ANOVA.

Wang Z, Bordas V, Deisboeck TS.

Front Physiol. 2011 Jul 5;2:35. doi: 10.3389/fphys.2011.00035. eCollection 2011.

4.

Discovering Molecular Targets in Cancer with Multiscale Modeling.

Wang Z, Bordas V, Deisboeck TS.

Drug Dev Res. 2011 Feb 1;72(1):45-52.

5.

Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model.

Wang Z, Bordas V, Sagotsky J, Deisboeck TS.

Math Med Biol. 2012 Mar;29(1):95-108. doi: 10.1093/imammb/dqq023. Epub 2010 Dec 8.

6.

Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine.

Moingeon P, Hrabina M, Bergmann KC, Jaeger S, Frati F, Bordas V, Peltre G.

Int Arch Allergy Immunol. 2008;146(4):338-42. doi: 10.1159/000121468. Epub 2008 Mar 21. Review.

PMID:
18362477
7.

Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification.

Heightman TD, Scott JS, Longley M, Bordas V, Dean DK, Elliott R, Hutley G, Witherington J, Abberley L, Passingham B, Berlanga M, de Los Frailes M, Wise A, Powney B, Muir A, McKay F, Butler S, Winborn K, Gardner C, Darton J, Campbell C, Sanger G.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6584-7. Epub 2007 Sep 25.

PMID:
17942309
8.

Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.

Witherington J, Blaney EL, Bordas V, Elliott RL, Gaiba A, Garton N, Green PM, Naylor A, Smith DG, Spalding DJ, Takle AK, Ward RW.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5538-41. Epub 2006 Aug 22.

PMID:
16931004
9.

Pyridone derivatives as potent and selective VLA-4 integrin antagonists.

Witherington J, Bordas V, Gaiba A, Green PM, Naylor A, Parr N, Smith DG, Takle AK, Ward RW.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2256-9. Epub 2006 Feb 7. Erratum in: Bioorg Med Chem Lett. 2006 Jun 15;16(12):3341.

PMID:
16455247
10.

6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

Witherington J, Bordas V, Gaiba A, Naylor A, Rawlings AD, Slingsby BP, Smith DG, Takle AK, Ward RW.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3059-62.

PMID:
12941333
11.

6-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

Witherington J, Bordas V, Gaiba A, Garton NS, Naylor A, Rawlings AD, Slingsby BP, Smith DG, Takle AK, Ward RW.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3055-7.

PMID:
12941332
12.

5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

Witherington J, Bordas V, Haigh D, Hickey DM, Ife RJ, Rawlings AD, Slingsby BP, Smith DG, Ward RW.

Bioorg Med Chem Lett. 2003 May 5;13(9):1581-4.

PMID:
12699760
13.

5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

Witherington J, Bordas V, Garland SL, Hickey DM, Ife RJ, Liddle J, Saunders M, Smith DG, Ward RW.

Bioorg Med Chem Lett. 2003 May 5;13(9):1577-80.

PMID:
12699759
14.

Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.

Witherington J, Bordas V, Cooper DG, Forbes IT, Gribble AD, Ife RJ, Berkhout T, Gohil J, Groot PH.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2177-80.

PMID:
11514164

Supplemental Content

Loading ...
Support Center